NFE2L2 and esophageal squamous cell carcinoma: Halofuginone-micelles show much reduced side effects with regard to suppressing hematopoietic and immune cells [121], demonstrating that halofuginone-micelles are promising NRF2 inhibitors for the treatment of NRF2-addicted ESCC.